<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088907</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02956</org_study_id>
    <secondary_id>ECOG-E1302</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT00088907</nct_id>
    <nct_alias>NCT00695760</nct_alias>
  </id_info>
  <brief_title>Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer</brief_title>
  <official_title>Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells
      from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by
      blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill
      more tumor cells. It is not yet known whether docetaxel is more effective with or without
      gefitinib in treating head and neck cancer. This randomized phase III trial is studying
      docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating
      patients with metastatic or locally recurrent head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the survival of poor prognosis patients with recurrent/metastatic squamous
      cell carcinoma of the head and neck treated with docetaxel with or without ZD1839 (Iressa,
      gefitinib).

      SECONDARY OBJECTIVES:

      I. To determine the time to progression and response rate in poor prognosis patients with
      recurrent/metastatic squamous cell carcinoma of the head and neck treated with docetaxel with
      or without ZD1839 (Iressa, gefitinib).

      II. To correlate the expression and activation status of the epidermal growth factor receptor
      (EGFR) signaling pathway with clinical outcome in the above patient population. The following
      specific biomarkers will be measured by immunohistochemistry on paraffin-embedded tumor
      tissue: EGFR, p-EGFR, AKT, p-AKT, Transforming growth factor (TGF)-alpha, Ki-67,
      extracellular-signal-regulated kinase (ERK), p-ERK, p70s6, p- p70s6 , and p27.

      III. To evaluate the frequency of common polymorphisms of Cytochrome P450 3A (CYP3A) and EGFR
      in this study population and the impact of these polymorphisms on survival, time to
      progression, response rate, and toxicities.

      IV. To analyze docetaxel and ZD1839 (Iressa, gefitinib) pharmacokinetics and to correlate
      polymorphisms with pharmacokinetic variability, response, toxicity, and other endpoints.

      V. To evaluate disease-related symptoms and overall quality of life among patients receiving
      docetaxel only to those receiving docetaxel and ZD1839 (Iressa, gefitinib).

      VI. To evaluate whether additional clinical benefit associated with ZD1839 (Iressa,
      gefitinib) can be detected as an improvement in patient-reported symptoms on the FACT Head
      and Neck Symptom Index (FHNSI)-10 and GP5.

      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
      are stratified according to treatment with prior chemotherapy (pretreated vs untreated),
      Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), weight loss
      within the past 6 months (&lt; 5% vs â‰¥ 5%), and prior cetuximab treatment (yes or no). Patients
      are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15
      and oral placebo once daily on days 1-28.

      Arm II: Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.

      In both arms, courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity. Patients in arm I who have disease progression may receive
      single-agent oral gefitinib once daily until further disease progression (which is called
      step 2 in the study).

      Quality of life is assessed at baseline, on days 15 and 28 of course 1, on day 28 of all
      subsequent courses, and at 2-4 weeks after completion of study treatment.

      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

      PROJECTED ACCRUAL: A total of 330 patients (165 per treatment arm) will be accrued for this
      study within 31.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was unlikely that the primary endpoint would be reached based on the fifth interim analysis
    results.
  </why_stopped>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
    <description>Overall survival is defined as time from registration to death from any cause. All eligible and treated patients were included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
    <description>Time to progression is defined as time from registration to disease progression. Disease progression was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions .
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
    <description>Tumor response was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Complete response (CR) was defined disappearance of all tumor lesions. Partial response (PR) was defined as as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. Overall response rate= CR+PR.
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Recurrent Head and Neck Cancer</condition>
  <condition>Metastatic Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (docetaxel and placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (docetaxel and gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (docetaxel and placebo)</arm_group_label>
    <arm_group_label>Arm II (docetaxel and gefitinib)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (docetaxel and placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (docetaxel and gefitinib)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and
             neck; patient must not have nasopharyngeal carcinoma of histologic types World Health
             Organization (WHO) 2 and 3

          -  Metastatic or locally recurrent carcinoma of the head and neck that is considered
             incurable by local therapies

          -  Any number of prior chemotherapy or biologic/targeted therapy regimens is allowed

          -  No prior systemic EGFR inhibitors, such as ZD1839 (Iressa, gefitinib)/Iressa
             (AstraZeneca), ABX-EBX (Abgenix), MDX-447 (Medarex/Merck), OSI-774/Tarceva (OSI
             pharmaceuticals), C225/Cetuximab (ImClone), PKI166 (Novartis), CI-1033 (Parke-Davis),
             EKB-569 (Wyeth Ayerst); treatment with paclitaxel is allowed if the patient did not
             progress while on paclitaxel

               -  NOTE: the use of cetuximab given concurrently with radiation or chemoradiotherapy
                  for up to 9 total weekly doses, as part of initial potentially curative therapy
                  is allowed, if completed &gt; 6 months prior to registration

          -  Patients must not receiving any other investigational agent while on the study

          -  Patients must have either:

               -  Strata A:

                    -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 (in bed
                       50% of the time. Ambulatory and capable of all self-care, but unable to
                       carry out any work activities; up and about more than 50% of waking hours),
                       AND no prior chemotherapy for recurrent metastatic head and neck cancer OR

               -  Strata B

                    -  PS 0-2 AND prior chemotherapy (i.e. one or more prior chemotherapy regimens
                       (without docetaxel)) for locally recurrent/metastatic disease or exposure to
                       prior chemotherapy (without docetaxel) as part of primary curative therapy &lt;
                       6 months prior to randomization; patients who receive chemotherapy as part
                       of potentially curative therapy of primary disease within 6 months of
                       randomization will be considered as having prior chemotherapy for
                       recurrent/metastatic disease, whereas patients who received chemotherapy as
                       part of potentially curative therapy of disease &gt; 6 months of randomization
                       will be considered as having no prior chemotherapy for recurrent/metastatic
                       disease

          -  Patients must have fully recovered from the effects of any prior surgery,
             chemotherapy, or radiation therapy

               -  A minimum time period of 3 weeks must elapse between the completion of radiation
                  therapy and randomization to the study

               -  A minimum period of 4 weeks must elapse between the last administration of any
                  prior chemotherapy and randomization to the study

               -  At least 2 weeks must elapse between the last administration of biologic/targeted
                  therapy and randomization to the study

               -  Patients must be &gt; 3 weeks since major surgery, or significant traumatic injury
                  prior to randomization

          -  Absolute neutrophil count (ANC) &gt;= 1500 /mm^3

          -  Platelets &gt;= 100,000 /mm^3

          -  Hemoglobin &gt;= 8.0 g/dl

          -  Bilirubin within normal limits

          -  Creatinine &lt; 2.0 or creatinine clearance of &gt; 60 ml/min

          -  All females of childbearing potential must have a blood test or urine study within 2
             weeks prior to randomization to rule out pregnancy

          -  Women of childbearing potential and sexually active males must use an accepted and
             effective method of contraception while on treatment and for three months after the
             completion of treatment

          -  Patients must have measurable or non-measurable disease based on Response Evaluation
             Criteria In Solid Tumors (RECIST); baseline measurements and evaluations must be
             obtained &lt; 4 weeks of randomization; all areas of disease should be recorded and
             mapped out in order to assess response and uniformity of response to therapy; disease
             in previously irradiated sites is considered measurable if there has been unequivocal
             disease progression or biopsy-proven residual carcinoma following radiation therapy;
             persistent disease after radiotherapy must be biopsy proven at least 8 weeks after
             completion of radiation therapy

               -  Radiographic findings are acceptable providing that clear-cut measurements can be
                  made

          -  Patients with a prior history of squamous cell or basal carcinoma of the skin or in
             situ cervical cancer must have been curatively treated. Patients with a history of
             other prior malignancy must have been treated with curative intent and must have
             remained disease-free for 5 years post diagnosis

          -  Drugs that are Cytochrome P450 3A4 (CYP3A4) inhibitors should be generally avoided and
             if possible, discontinued, 1 week prior to initiating study drug; however, if
             medically necessary, they can be taken with caution after consulting with the study
             chair

          -  From patients consenting to participate in the correlative studies:

               -  Tissues must be submitted as outlined in Section 10; if tissue cannot be
                  submitted, written justification must be submitted to the ECOG Pathology
                  Coordinating Office

        Exclusion criteria:

          -  Prior therapy with docetaxel at any time (even if part of prior curative treatment)

          -  Unstable systemic disease, including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, or serious arrhythmia requiring medication

          -  Hypercalcemia related to head and neck cancer

          -  Brain metastasis

          -  Current peripheral neuropathy &gt;= grade 2 at time of randomization

          -  Patients have co-existing condition that would preclude full compliance with the study

          -  Known hypersensitivity to ZD1839 (Iressa, gefitinib) or any excipients of this
             product; prior history of severe hypersensitivity reaction to Docetaxel or other drugs
             formulated with polysorbate 80

          -  HIV positive patient's receiving combination anti-retroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with ZD1839 (Iressa,
             gefitinib)

          -  Patients have had tumor-related hemorrhagic events in the previous three months that
             required as major medical intervention, such as surgery or embolization

          -  Patients are on therapeutic anticoagulation or have tumors that are unequivocally
             invading major vessels (e.g. carotid artery)

          -  Females are pregnant or breast feeding because chemotherapy may be harmful to the
             fetus or the nursing infant; also, the effects of ZD1839 (Iressa, gefitinib) on the
             developing human fetus are unknown
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanassios Argiris</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.</citation>
    <PMID>23460714</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <results_first_submitted>March 20, 2015</results_first_submitted>
  <results_first_submitted_qc>April 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2015</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>docetaxel</keyword>
  <keyword>gefitinib</keyword>
  <keyword>head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was activated on August 6,2004 and terminated on November 13,2008. A total of 270 patients (136 on arm I and 134 on arm II) was enrolled to first step of the study. In July 2007, registration to step 2 (single ZD1839 therapy) was suspended because other study indicated lack of good benefit/risk profile of single agent ZD1839.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Docetaxel and Placebo)</title>
          <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Docetaxel and Gefitinib)</title>
          <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
gefitinib: Given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Study (Step 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Treated</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Treatment would continue until disease progression, no certain fixed number of cycles.</participants>
                <participants group_id="P2" count="0">Treatment would continue until disease progression, no certain fixed number of cycles</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown/not specify</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible or not start protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Single Gefitinib Treatment (Step 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24">Patients on Arm I could cross over to gefitinib after disease progression on step 1.</participants>
                <participants group_id="P2" count="0">Cross over to single gefitinib therapy at progression was allowed for patients on Arm I only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown/not specify</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not start protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary population was eligible and treated patients in the study. All study results were based on the primary population except for adverse event results. In total, 136 patients enrolled on arm I, but 19 patients were ineligible/no protocol therapy. 134 patients entered arm II, 12 of them were not eligible/not starting protocol therapy.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Docetaxel and Placebo)</title>
          <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Docetaxel and Gefitinib)</title>
          <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
gefitinib: Given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="28" upper_limit="86"/>
                    <measurement group_id="B2" value="60" lower_limit="41" upper_limit="84"/>
                    <measurement group_id="B3" value="60" lower_limit="28" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as time from registration to death from any cause. All eligible and treated patients were included in the analysis.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
        <population>eligible and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Docetaxel and Placebo)</title>
            <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Docetaxel and Gefitinib)</title>
            <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
gefitinib: Given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as time from registration to death from any cause. All eligible and treated patients were included in the analysis.</description>
          <population>eligible and treated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="4.93" upper_limit="7.43"/>
                    <measurement group_id="O2" value="7.33" lower_limit="5.75" upper_limit="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to progression is defined as time from registration to disease progression. Disease progression was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions .
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
        <population>eligible and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Docetaxel and Placebo)</title>
            <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Docetaxel and Gefitinib)</title>
            <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
gefitinib: Given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression is defined as time from registration to disease progression. Disease progression was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions .
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
          <population>eligible and treated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="1.97" upper_limit="3.48"/>
                    <measurement group_id="O2" value="3.55" lower_limit="2.76" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Tumor response was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Complete response (CR) was defined disappearance of all tumor lesions. Partial response (PR) was defined as as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. Overall response rate= CR+PR.
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.</time_frame>
        <population>eligible and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Docetaxel and Placebo)</title>
            <description>Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Docetaxel and Gefitinib)</title>
            <description>Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression.
docetaxel: Given IV
gefitinib: Given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Tumor response was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Complete response (CR) was defined disappearance of all tumor lesions. Partial response (PR) was defined as as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. Overall response rate= CR+PR.
Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).
All eligible and treated patients were included in the analysis.</description>
          <population>eligible and treated patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.4" upper_limit="9.7"/>
                    <measurement group_id="O2" value="9.8" lower_limit="5.2" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every cycle (1 cycle = 4 weeks) while on treatment and for the 30 days following the last dose of protocol drug (which was included in the form for the last cycle).</time_frame>
      <desc>Prior to diagnosis of progression / relapse or after start of non-protocol therapy, severe (Grade â‰¥ 3) long term toxicity that has not been previously reported was included in the report as well.</desc>
      <group_list>
        <group group_id="E1">
          <title>Step 1: Docetaxel+Placebo</title>
          <description>Premedication: Dexamethasone
Docetaxel as a 60 m inute infusion 35mg/m2 to be given on days 1,8,and 15 of a 28-day schedule
Placebo one tablet daily orally starting on day 1. Treatment to continue from days 1-28 of each cycle.</description>
        </group>
        <group group_id="E2">
          <title>Step 1: Docetaxel+ZD1839</title>
          <description>Premedication: Dexamethasone
Docetaxel as a 60 m inute infusion 35mg/m2 to be given on days 1,8, and 15 of a 28-day schedule.
ZD1839 (Iressa, gefitinib) 250 mg/daily orally starting on day 1. Treatment to continue from days 1-28 of each cycle.</description>
        </group>
        <group group_id="E3">
          <title>Step 2: ZD1839</title>
          <description>ZD1839 (Iressa, gefitinib) 250 mg/daily orally starting on day 1. Treatment to continue from days 1-28 of each cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury to carotid artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time pr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecif</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal di</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndro</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

